<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Applying a next-generation sequencing assay targeting 145 cancer-relevant genes in 40 colorectal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and 24 non-<z:e sem="disease" ids="C0149925" disease_type="Neoplastic Process" abbrv="SCLC">small cell lung cancer</z:e> formalin-fixed paraffin-embedded tissue specimens identified at least one clinically relevant genomic alteration in 59% of the samples and revealed two gene fusions, C2orf44-ALK in a <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> sample and KIF5B-RET in a <z:mp ids='MP_0002027'>lung adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Further screening of 561 <z:mp ids='MP_0002027'>lung adenocarcinomas</z:mp> identified 11 additional <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> with KIF5B-RET gene fusions (2.0%; 95% CI 0.8-3.1%) </plain></SENT>
<SENT sid="2" pm="."><plain>Cells expressing oncogenic KIF5B-RET are sensitive to multi-kinase inhibitors that inhibit RET </plain></SENT>
</text></document>